#GI25 highlights #CommunityOnc: 1. #SCIENCE: Adv Eso SCC 2. #ESOPEC publication (Eso/GEJ/Ga) 3. Chemo in resectable Panc Ca 4. #StarterNET: GEP-NET 5. #CM8HW: dMMR/MSI-H mCRC 6. #BREAKWATER: BRAFV600E mCRC 7. ctDNA: #BESPOKE + SWOG80702 #OncSky #gism @ascocancer.bsky.social 1/8
🔥NRG GI-007🔥 LA-Esophagus Carcinoma 🔍 dCRT (50.4 Gy/28 fx carbo/taxol) + endoscopically injected oncolytic virus OBP-301 ✅💯 cCR rate❗️ ✅Comparatively favorable AE profile 👏🏽👏🏽 Brilliant work and looking forward to future study!! #GI25 @ascocancer.bsky.social
🚨Pooled CAO/ARO/AIO-12 and OPRA Rectal trials🚨 Study suggests that selective WW compared with planned surgery offers: ✅ Comparable OS and DFS!! 🔥 Supports WW as a highly appropriate, and potentially preferable, option for patients with cCR after TNT‼️ #GI25 #CRC @ascocancer.bsky.social
🔥🔥🔥BREAKWATER🔥🔥🔥 BRAF V600E mut #CRC SOC (FOLFOX) +/- encorafenib + cetuximab EC + FOLFOX shows: ✅⬆️ORR ✅Strong suggestion of ⬆️OS 🚨EC + FOLFOX is a new SOC‼️ Pub available: idp.nature.com/authorize?re... #GI25 @ascocancer.bsky.social
🚨🚨CheckMate 8HW🚨🚨 🔥NEW SOC🔥 dMMR/MSI-H mCRC Ph3 RCT 🔍 Nivo vs Ipi + Nivo Ipi + Nivo offers: ✅⬆️ Early and sustained PFS ✅favorable safety profile Pub available: www.thelancet.com/journals/lan... #GI25 #crc @ascocancer.bsky.social
🚨SCIENCE Ph3 RCT🚨 🔥Check this one out!🔥 cT2-4N0-3, T1N2-3 Eso SCC 1️⃣neo Carbo + nab Paclitaxel + Sintilimab 2️⃣nCRT (41.4/23) w/ Carbo-taxol + Sintilimab 3️⃣nCRT ✅⬆️⬆️pCR CRT vs chemo (only 13% with chemo) ✅Sintilimab + CRT ⬆️ pCR (47%➡️60%) without added AEs #GI25 @ascopost.bsky.social
